Cargando…
Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a heterogeneous malignant disorder of hematopoietic progenitor cells in which several genetic and epigenetic aberrations have been described. Despite progressive advances in our understanding of the molecular biology of this disease, the outcome for most patients is p...
Autores principales: | Arriazu, Elena, Pippa, Raffaella, Odero, María D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822158/ https://www.ncbi.nlm.nih.gov/pubmed/27092295 http://dx.doi.org/10.3389/fonc.2016.00078 |
Ejemplares similares
-
A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia
por: Arriazu, Elena, et al.
Publicado: (2020) -
MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia
por: Pippa, Raffaella, et al.
Publicado: (2016) -
Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia
por: Ramaswamy, Kavitha, et al.
Publicado: (2015) -
The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias
por: Pippa, Raffaella, et al.
Publicado: (2020) -
Therapeutic targeting of leukemia stem cells in acute myeloid leukemia
por: Barbosa, Karina, et al.
Publicado: (2023)